ROVI and UCB end their commercial relationship with regards to Cimzia

ROVI – ROVI and UCB end their commercial relationship with regards to Cimzia® 1 Para más información: Marta Campos Martínez [email protected] Tel: +34 91 244 44 22 ROVI and UCB end their commercial relationship with regards to Cimzia®  Cimzia® (certolizumab pegol), for the treatment of rheumatoid arthritis disease, has been jointly co-promoted in Spain by ROVI and UCB until now.  Both companies have agreed that, from 1 st of September, Cimzia ® will be promoted and commercialised exclusively by UCB in Spain. Most of the ROVI sales team that promoted Cimzia ® among the healthcare professionals will join UCB staff. Madrid – 3 September 2012– Laboratorios Farmacéuticos Rovi (ROVI) and UCB have reached an agreement under which they have ended their commercial relationship with regards to Cimzia ® (certolizumab pegol), PEGylated anti-TNF alpha drug for the treatment of rheumatoid arthritis disease. Since 15th of June 2010, Cimzia ® had been jointly co-promoted in Spain by ROVI and UCB. In this period and as a result of the activities carried out by ROVI, Cimzia ® is available in more than 80% of the key public hospitals, which means that more than 85% of the Spanish population already has access to the drug and can benefit from its clinical efficiency, shown by a significant improvement in the quality of life of the patients treated. Under this agreement, Cimzia ® will be promoted and commercialised exclusively by UCB in Spain from 1 st of September. Most of the ROVI sales team that promoted Cimzia ® among the healthcare professionals will join UCB staff. ROVI – ROVI and UCB end their commercial relationship with regards to Cimzia® 2 ROVI will continue to commercialise and promote its Rheumatology product portfolio in osteoarticular pathology, as well as continuing to develop its business within the hospital sector. About ROVI ROVI is a fully integrated Spanish specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and marketing of small molecule and specialty biologic drugs. The Company has a diversified portfolio of products that it markets in Spain through its specialized sales force, calling on specialist physicians, hospitals and pharmacies. ROVI’s portfolio of 30 principal marketed products is currently anchored by the internally- developed, second generation low molecular weight heparin, Bemiparin. ROVI’s research and development pipeline is focused primarily on the expansion of applications, indications and alternative mechanisms of action for the heparin-derived products and other glycosaminoglycans and on the development of new controlled release mechanisms based on ISMTM technology, with the aim of obtaining new pharmaceutical products that enable the regular administration of formulations which are administered daily in chronic and prolonged treatments. ROVI manufactures the active biological ingredient (Bemiparin) for its principal proprietary products and for injectable pharmaceutical products developed by its in-house research team, and utilizes its state-of-the-art filling and packaging capabilities to provide a broad array of toll manufacturing services to leading international pharmaceutical companies, primarily in the area of pre-filled syringes. In addition, ROVI provides contract manufacturing and packaging services of solid oral pharmaceutical dosage forms, using the most enhanced technology, Roller Compaction. Additional information about ROVI is available on the company’s website: www.rovi.es

The release as fetched from its publisher. rovi.es ↗